Regulatory Perspectives on Reverse Logistics of Pharmaceutical Products: A Comparative Study of India and Regulated Countries

Abstract

Reverse logistics has emerged as a critical component of pharmaceutical supply chain management, ensuring the safe collection, transportation, recall, and disposal of expired, damaged, recalled, and unused medicines. Inadequate management of returned pharmaceutical products can lead to environmental contamination, public health risks, economic losses, and the re-entry of substandard medicines into the supply chain. Although developed countries such as the United States, European Union member states, Japan, Canada, and Australia have established comprehensive regulatory frameworks supported by serialization, track-and-trace technologies, and structured medicine take-back programs, India continues to face significant regulatory and operational challenges in pharmaceutical reverse logistics. The present study aims to compare the reverse logistics regulatory frameworks of India with those of regulated countries and identify gaps in the Indian pharmaceutical system. A comprehensive review of regulatory guidelines, scientific literature,and international policies was conducted, supplemented by an industry survey involving pharmaceutical manufacturers, distributors, wholesalers, and retailers. The study also evaluates the applicability of the Define–Measure–Analyze–Improve–Control (DMAIC) methodology for strengthening pharmaceutical reverse logistics. The findings indicate that India's existing regulatory framework lacks a comprehensive and legally enforceable system for medicine recalls, product traceability, post-consumer medicine collection, and environmentally safe disposal. In contrast, regulated countries have implemented robust recall classifications, digital traceability systems, Good Distribution Practices (GDP), Extended Producer Responsibility (EPR), and well-defined reverse distribution mechanisms. The study proposes a regulatory framework tailored to India's pharmaceutical sector that integrates risk-based recall procedures, digital tracking technologies, standardized disposal protocols, and stakeholder accountability. The proposed framework has the potential to improve patient safety, prevent the circulation of counterfeit and expired medicines, minimize environmental pollution, enhance regulatory compliance, and strengthen India's pharmaceutical supply chain sustainability.